• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Orphazyme

edit

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

Recent Milestones

edit

• 
  Orphazyme received $20M in Series A funding. (9/7/11)
  Posted 9/7/11 at 6:46pm via fiercebiotech.com
• 
  Orphazyme received () in Seed funding. (2/14/11)
  Posted 3/27/11 at 5:25pm via orphazyme.com
• 
  Orphazyme added Anders Mørkeberg Hinsby as CEO.
  Posted 3/27/11 at 5:25pm

Videos

Screenshots

edit

Sources

1. Orphazyme raises 22 mDKK in a seed round extension; Sunstone Capital joins as new investor (orphazyme.com) [edit]
2. Orphazyme lands $20M A round to back new drugs for rare genetic disorder (fiercebiotech.com) [edit]